Investigation into Medication Import and Sales Irregularities
The Financial Crime and Money Laundering Combating Agency revealed violations and financial and legal irregularities involving a pharmaceutical import company. These issues relate to tax evasion and speculation in the pharmaceutical market. The investigation clarified that the company imported medicines through official documentary credits but sold them in the market with profit margins ranging from 100% to 300%, despite submitting documents indicating that it was a loss-making company. It was also found that the company siphoned off quantities of medicines designated for public entities and sold them unlawfully in the market. A official was apprehended, and legal procedures against them have been halted to allow for further investigations into these violations.
Notice: This Is an AI-Generated Summary
Comments (0)